Campaign

  • Home/
  • Aurigen Medical 5
CRO#: 612988

Aurigen Medical 5

MedTech

AuriGen Medical, a clinical-stage MedTech firm, is transforming stroke prevention with its Zenith device. Promising clinical results position it for rapid growth.
by Dr. John Thompson
Galway
309% Funded
€ 500,000 Funding goal
€ 1,544,197 Invested
187Investors


Company Summary :

 

AuriGen Medical is transforming stroke risk in patients with atrial fibrillation (AF) through its next-generation heart implant, Zenith. Following 100% technical success and zero complications in First-in-Human trials, AuriGen has recently won a 2nd DTIF non-dilutive Grant of €6.3M and strong investor backing to accelerate its next growth phase. Final €1M available in the Pre-Series A bridge round. Invest now to join our mission redefining stroke prevention in AF patients.

 

Key Highlights (short version)

 

  • Breakthrough Clinical Validation: 100% technical success and zero complications in First-in-Human trial, confirming Zenith’s potential to transform stroke risk reduction in AF patients.
  • Recently won €6.3M Non-Dilutive Funding: Backed by Ireland’s DTIF, accelerating AuriGen’s next growth phase.
  • Clinician-Led Investment: Several leading European cardiologists invested directly, reinforcing deep clinical confidence.
  • Expanding Market: LAAO market growing from $2B to $10B by 2032 (25–30% CAGR); Boston Scientific reports 28% YoY growth.
  • Next-Gen Device: Fully repositionable with real-time seal verification, a safer, simpler, and more precise solution designed to meet the complex needs of high-stroke-risk patients.
  • Strategic Momentum: Multiple venture investors and two global MedTech strategics actively engaged, reflecting strong market confidence.
  • Value Inflection Ahead: DTIF grant and bridge funding enable early Series A activities, accelerating progress and bringing forward the next major value inflection for shareholders.

 

 

  • Campaign Story
  • Team
  • Documents
  • FAQ
  • Updates
  • Discussion

Risk warning

Investing in start-ups and early-stage businesses involves significant risks, including illiquidity, lack of dividends, loss of capital and dilution. Such investments should only be made as part of a well-diversified portfolio.

The service offered by Spark Venture Funding is intended solely for investors who are sufficiently knowledgeable and experienced to understand these risks and to make their own investment decisions. You will only be able to invest in opportunities on the Spark Venture Funding platform once you have been assessed as sufficiently sophisticated.

Investment opportunities presented on the platform are not offers to the public. Investments can only be made by registered members of Spark Venture Funding, based on the information provided by the companies raising capital. Neither Spark Venture Funding nor any of its representatives accepts responsibility for this information or for any recommendations or opinions made by the companies. We strongly recommend that all private investors seek advice from a qualified professional advisor before investing in any opportunity on the Spark Venture Funding platform.

Please click here to read our full Risk Warning.

Spark Venture Funding is authorised by the Central Bank of Ireland.